Why Age Spots Come Back After Laser Treatment, and What Actually Prevents Recurrence

One of the most common frustrations in pigment treatment goes like this: a patient has a solar lentigo, commonly called an age spot, removed with a Q-switched or picosecond laser. The spot crusts, flakes off, and the skin looks even. Six to twelve months later, a brown patch reappears in the same place. Patients often assume the device failed or the operator did something wrong. In most cases, neither is true.

What a laser actually removes

An age spot is not a stain sitting on top of the skin. It is a patch of epidermis where melanocytes, the pigment producing cells, have been pushed into overdrive by years of ultraviolet exposure. These cells produce excess melanin and hand it off to surrounding keratinocytes, the ordinary skin cells that make up the visible surface. Pigment specific lasers such as Q-switched Nd:YAG, Q-switched alexandrite, and picosecond devices work through selective photothermolysis: an extremely short pulse of light is absorbed by melanin, shattering pigment granules while sparing the surrounding tissue. The fragmented pigment is then cleared by the immune system or shed with the crust.

Here is the critical point. The laser destroys the melanin and often damages the most heavily pigmented cells, but it does not reliably eliminate every altered melanocyte in the lesion, and it does nothing to reverse the underlying photodamage in the surrounding skin. Solar lentigines also carry characteristic changes in the epidermis itself, including elongated rete ridges and, in many lesions, mutations in genes such as FGFR3 that keep pigment production dialed up. Surviving melanocytes retain that programming.

Two different kinds of "coming back"

Recurrence is not one phenomenon. Clinicians generally distinguish two patterns, and they matter because the fixes are different.

The first is true recurrence, where residual melanocytes in the treated lesion gradually resume overproduction of melanin, usually accelerated by new ultraviolet exposure. Published follow up data on laser treated lentigines suggest recurrence rates in roughly the 10 to 25 percent range within a year, higher in patients who do not use sun protection consistently. The spot that returns typically looks similar to the original, appears in the same footprint, and darkens with sun.

The second is postinflammatory hyperpigmentation, or PIH. This is not the old spot returning but a new pigment response triggered by the inflammation of the treatment itself. PIH tends to appear within two to eight weeks of the procedure, often looks slightly grayer or more diffuse than the original lentigo, and is far more common in medium to deep skin tones, roughly Fitzpatrick types III through VI. Studies of Q-switched laser treatment in Asian populations have reported PIH rates anywhere from 10 to over 40 percent depending on device settings and aftercare. Picosecond lasers, which deliver energy in shorter pulses with less heat diffusion, appear to lower this risk somewhat but do not eliminate it.

Distinguishing the two matters. True recurrence may justify retreatment. PIH usually should not be lasered again quickly, because more inflammation can worsen it. It often fades over three to twelve months and responds to topical agents and strict photoprotection.

What actually reduces the odds of return

The single most protective factor, and this is consistent across the literature, is rigorous ultraviolet avoidance after treatment. Ultraviolet radiation is the original driver of the lesion and the fastest route to reactivating surviving melanocytes. That means broad spectrum sunscreen of SPF 30 or higher applied daily and reapplied during prolonged exposure, plus hats and shade during peak hours. For patients prone to pigmentation, tinted sunscreens containing iron oxides add value because they also block visible light, which stimulates melanogenesis in darker skin types through the opsin 3 receptor pathway.

Second, topical maintenance therapy has reasonable mechanistic and clinical support. Agents that slow melanin production, such as hydroquinone in short supervised courses, azelaic acid, tranexamic acid, or retinoids that accelerate turnover of pigmented keratinocytes, can suppress the low grade pigment rebound that follows treatment. Several trials pairing laser treatment with a topical regimen have shown lower recurrence and PIH rates than laser alone.

Third, appropriate device selection and conservative settings matter more than marketing suggests. In darker skin tones, longer wavelengths such as 1064 nm, lower fluences, and picosecond pulse durations reduce collateral injury to normal melanocytes. Intense pulsed light, while effective for lighter skin types with diffuse sun damage, carries higher PIH risk in deeper skin tones because its broadband output is absorbed less selectively.

The honest framing

No current treatment changes the fact that a lentigo prone patch of skin remains lentigo prone. Laser removal is best understood as resetting the visible pigment, not curing the underlying photodamage. Patients who go in expecting permanent one time results are often disappointed. Patients who treat removal as the first step in a maintenance plan, anchored by daily photoprotection, generally stay clear far longer. One caution applies to every case: any spot that recurs with irregular borders, multiple colors, rapid growth, or texture change should be evaluated by a dermatologist before retreatment, because lasering an unrecognized lentigo maligna can delay a melanoma diagnosis.

Related reading: Why Treated Age Spots Come Back: The Biology of Recurrence, Explained.